Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1982 Nov;50(2):442–449.

Serum stimulatory activity and polymorphonuclear leucocyte movement in patients with fulminant hepatic failure.

R J Wyke, A G Yousif-Kadaru, I A Rajkovic, A L Eddleston, R Williams
PMCID: PMC1536673  PMID: 7151333

Abstract

Serum from 27 patients with fulminant hepatic failure and grade IV encephalopathy had reduced ability to stimulate the movement in vitro of normal polymorphonuclear leucocytes. All patients had a deficiency of serum complement factors C3 and C5 and there was a significant positive correlation between C5 and serum stimulatory activity. However, in addition to this complement defect, serum from 22% of patients contained an antagonist to normal serum stimulatory factors. This antagonism was attributed to at least two different substances in the serum on the basis of differences in heat lability, dialysability and action on complement factor C5a. Polymorphonuclear leucocytes from eight of 13 patients had reduced movement toward serum, but serum from only one patient contained an antagonist acting on the cells; this was probably related to an underlying carcinoma of the breast. During the early stages of clinical recovery, serum stimulatory and complement activity returned to normal. These serum and cellular defects have not been reported previously in patients with fulminant hepatic failure and represent major defects in the body's defenses against bacterial infection.

Full text

PDF
442

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aggett P. J., Harries J. T., Harvey B. A., Soothill J. F. An inherited defect of neutrophil mobility in Shwachman syndrome. J Pediatr. 1979 Mar;94(3):391–394. doi: 10.1016/s0022-3476(79)80578-8. [DOI] [PubMed] [Google Scholar]
  2. Anderson R., Jones P. T. Increased leucoattractant binding and reversible inhibition of neutrophil motility mediated by the peroxidase/H2O2/halide system: effects of ascorbate, cysteine, dithiothreitol, levamisole and thiamine. Clin Exp Immunol. 1982 Feb;47(2):487–496. [PMC free article] [PubMed] [Google Scholar]
  3. Ballow M., Shira J. E., Harden L., Yang S. Y., Day N. K. Complete absence of the third component of complement in man. J Clin Invest. 1975 Sep;56(3):703–710. doi: 10.1172/JCI108141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Beebe D. P., Ward P. A., Spitznagel J. K. Isolation and characterization of an acidic chemotactic factor from complement-activated human serum. Clin Immunol Immunopathol. 1980 Jan;15(1):88–105. doi: 10.1016/0090-1229(80)90023-9. [DOI] [PubMed] [Google Scholar]
  5. Canalese J., Wyke R. J., Vergani D., Eddleston A. L., Williams R. Circulating immune complexes in patients with fulminant hepatic failure. Gut. 1981 Oct;22(10):845–848. doi: 10.1136/gut.22.10.845. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. DeMeo A. N., Andersen B. R. Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med. 1972 Apr 6;286(14):735–740. doi: 10.1056/NEJM197204062861401. [DOI] [PubMed] [Google Scholar]
  7. Gazzard B. G., Portmann B., Murray-Lyon I. M., Williams R. Causes of death in fulminant hepatic failure and relationship to quantitative histological assessment of parenchymal damage. Q J Med. 1975 Oct;44(176):615–626. [PubMed] [Google Scholar]
  8. Maderazo E. G., Anton T. F., Ward P. A. Serum-associated inhibition of leukotaxis in humans with cancer. Clin Immunol Immunopathol. 1978 Feb;9(2):166–176. doi: 10.1016/0090-1229(78)90068-5. [DOI] [PubMed] [Google Scholar]
  9. Mummery R. V., Bradley J. M., Jeffries D. J. Microbiological monitoring of patients in hepatic failure with particular reference to extracorporeal porcine liver perfusion. Lancet. 1971 Jul 10;2(7715):60–64. doi: 10.1016/s0140-6736(71)92042-3. [DOI] [PubMed] [Google Scholar]
  10. Nusinovici V., Crubille C., Opolon P., Touboul J. P., Darnis F., Caroli J. Hépatites fulminantes avec coma. Revue de 137 cas. I. Complications. Gastroenterol Clin Biol. 1977;1(11):861–873. [PubMed] [Google Scholar]
  11. Van Epps D. E., Strickland R. G., Williams R. C., Jr Inhibitors of leukocyte chemotaxis in alcoholic liver disease. Am J Med. 1975 Aug;59(2):200–207. doi: 10.1016/0002-9343(75)90354-x. [DOI] [PubMed] [Google Scholar]
  12. Ward P. A., Berenberg J. L. Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med. 1974 Jan 10;290(2):76–80. doi: 10.1056/NEJM197401102900203. [DOI] [PubMed] [Google Scholar]
  13. Ward P. A., Goralnick S., Bullock W. E. Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med. 1976 Jun;87(6):1025–1032. [PubMed] [Google Scholar]
  14. Wyke R. J., Canalese J. C., Gimson A. E., Williams R. Bacteraemia in patients with fulminant hepatic failure. Liver. 1982 Mar;2(1):45–52. doi: 10.1111/j.1600-0676.1982.tb00177.x. [DOI] [PubMed] [Google Scholar]
  15. Wyke R. J., Rajkovic I. A., Eddleston A. L., Williams R. Defective opsonisation and complement deficiency in serum from patients with fulminant hepatic failure. Gut. 1980 Aug;21(8):643–649. doi: 10.1136/gut.21.8.643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Yousif-Kadaru A. G., Wyke R. J., Rajkovic I. A., Eddleston A. L., Williams R. Defects of serum chemoattraction and polymorphonuclear leucocyte movement in patients with primary hepatocellular carcinoma. Clin Exp Immunol. 1982 Aug;49(2):467–473. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES